Cxbladder Commercial Evaluation Confirms Clinical Outperformance
21st December 2020

Peer reviewed publication of further independent, real-world clinical evidence highlights the effectiveness, safety and long term clinical utility from inclusion of Cxbladder in a new standard of care in mainstream clinical use. Read More

Pacific Edge Notified of Positive LCD Decision for Cxbladder in USA
03rd July 2020

Transformational reimbursement milestone for Pacific Edge with the notification of LCD coverage for CMS patients in the USA. The LCD coverage facilitates reimbursement for CMS patients using Cxbladder Detect and Cxbladder Monitor. Read More

Kaiser Permanente Approves Commercial use of Cxbladder
17th June 2020

It gives us great pleasure to announce that Pacific Edge Limited and Kaiser Permanente have reached an agreement for the commercial use of our Cxbladder tests. Read More

Renowned US Oncologist & Author Recommends Cxbladder
18th May 2020

Renowned Oncologist and Author Dr Mark Scholz discusses the benefits of Cxbladder as a substitute for cystoscopy during an interview on Prostate Cancer and the implications of blood in urine. Read More

New Webinar: Alternative Strategies to Deliver Bladder Cancer Investigation During COVID-19 & Beyond
30th April 2020

In a discussion led by Neal Shore, MD, on the high profile UroToday platform, two influential urologists discuss their use of Cxbladder’s In-Home Sampling Programme and how it is currently being used by different urologists around the US to streamline patient care. Read More

Public Health Providers Increase Commercial Use of Cxbladder
06th April 2020

Pacific Edge are pleased to announce that two of New Zealand’s largest public healthcare providers – Counties Manukau Health and Waitematā District Health Board - are extending their commercial use of Cxbladder. Read More

Pacific Edge to Continue Providing Essential Diagnostic Services
25th March 2020

Pacific Edge will continue to provide essential cancer diagnostic services during the COVID-19 shutdown in both New Zealand and USA. Read More

Real World Evidence Highlights Clinical Utility of Cxbladder
12th February 2020

Cancer diagnostics company, Pacific Edge Limited (PEB: NZX) has today announced the publication of further real world evidence of significant gains in clinical utility from the commercial adoption of Cxbladder Monitor (CxbM) by several of New Zealand’s public healthcare providers. Read More